(Q41602462)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Association of serum IFN-λ3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

17

Namiki Izumi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Yoshihiko Aoki

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masaya Sugiyama

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Kazumoto Murata

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Sachiyo Yoshio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masayuki Kurosaki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Satoru Hashimoto

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hiroshi Yatsuhashi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hideyuki Nomura

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jong-Hon Kang

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Shigeko Naito

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Tatsuji Kimura

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yoko Yamagiwa

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masaaki Korenaga

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masatoshi Imamura

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Naohiko Masaki

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masayoshi Kage

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Masashi Mizokami

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Tatsuya Kanto

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

14 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

894-902

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

Global control of hepatitis C: where challenge meets opportunity

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Antiviral therapy for chronic hepatitis C: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Current and future therapies for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Therapy of hepatitis C--back to the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Antiviral strategies in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleuk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Hepatic stellate cell protrusions couple platelet-derived growth factor-BB to chemotaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

The Marburg I variant (G534E) of the factor VII-activating protease determines liver fibrosis in hepatitis C infection by reduced proteolysis of platelet-derived growth factor BB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Anti-PDGF-B monoclonal antibody reduces liver fibrosis development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

IFN-lambda determines the intestinal epithelial antiviral host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Genetic variation of the IL-28B promoter affecting gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Interferon-lambda serum levels in hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Serum IP-10 Levels Correlate with the Severity of Liver Histopathology in Patients Infected with Genotype-1 HCV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-014-1023-2

Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25501286

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00535-014-1023-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25501286%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference